Kathleen Scott - 02 Jan 2025 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Role
Chief Financial Officer
Signature
/s/ Kathleen Scott, Attorney-in-Fact
Issuer symbol
SPRY
Transactions as of
02 Jan 2025
Transactions value $
$0
Form type
4
Filing time
03 Jan 2025, 16:30:33 UTC
Previous filing
10 Dec 2024
Next filing
14 Jan 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPRY Stock option (right to buy) Award $0 +176,700 $0 176,700 02 Jan 2025 Common Stock 176,700 $10.71 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2025.